Diabetes CV Studies Spur Questions On Statistical Methods, Data Integrity

The need to conduct cardiovascular safety assessments for new type 2 diabetes drugs has raised concerns within FDA and industry about statistical methods, data confidentiality and blinding for CV outcomes studies.